Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months. This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio s genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with newly diagnosed glioblastoma.
Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92% of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months.
Shortly before her 34th birthday, King was diagnosed with a grade 2 astrocytoma tumor in her right temporal lobe, and it could not be removed without cutting out part of her brain. Thanks to a clinical trial at UAB, her.
UAB is already a national leader in clinical trials Here is how it plans to extend the benefits to even more Alabamians uab.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uab.edu Daily Mail and Mail on Sunday newspapers.
Kallie McDonald says following her heart and passion put her in a position to help women suffering from the same illness as her mom. Written by: Katherine Kirk Media contact: Brianna Hoge Kallie McDonald says following h.